explore -WSS

explore

author：knowledge 2025-10-01 20:15:04 - browse：42

A psilocybin mushroom lays inside a clear capsule — Adobe

A single dose of psilocybin may have enduring benefits for people with major depressive disorder, according to a randomized clinical trial published Thursday in the Journal of the American Medical Association.

Several prior studies have suggested that psilocybin, the psychedelic compound produced by certain types of mushrooms, could be a promising way to treat major depression in people for whom antidepressants or counseling aren’t effective. But those studies mostly focused on short-term results, while the new JAMA study looked at psilocybin’s efficacy up to six weeks after the administration of a single dose of psilocybin.

“It’s exciting to see another study that’s coming out that is adding to the evidence base suggesting potential efficacy of psilocybin for depression, amongst other conditions,” said Greg Fonzo, an assistant professor and co-director for the Center for Psychedelic Research and Therapy at the University of Texas at Austin’s Dell Medical School, who was not involved in the study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Medicare details structure of new drug price negotiation program

WSS

BioMarin wins approval for gene therapy to treat hemophilia A

Bill would allow buprenorphine prescription for addiction via telehealth

Infant mortality in U.S. rose last year for first time in decades: CDC

Kidney transplant patients stopped immunosuppressants in trial

Drug repurposing or repositioning? The language matters

Alkermes shareholders re

focus

explore

entertainment

Medical records are filled with copy

Live blog: Hearing on CRISPR

Medical leaders decry Supreme Court decision on affirmative action

New air purifier tech could be key to improving indoor air quality

The cancer drug shortage isn’t new — and neither are the solutions

How to convince healthy people to buy insurance

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare must police algorithms in Medicare Advantage, Dems say

George Santos makes 1st court appearance after pleading not guilty to 13 counts

All of Us, NIH's precision medicine initiative, gets a big boost

explore

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Medicare proposal to cover medical devices draws a mixed reaction

Medicare details structure of new drug price negotiation program

Alkermes shareholders re

hotspot

focus

hotspot

hotspot